CA3068363A1 - Identification and elimination of damaged and/or senescent cells - Google Patents

Info

Publication number

CA3068363A1

CA3068363A1 CA3068363A CA3068363A CA3068363A1 CA 3068363 A1 CA3068363 A1 CA 3068363A1 CA 3068363 A CA3068363 A CA 3068363A CA 3068363 A CA3068363 A CA 3068363A CA 3068363 A1 CA3068363 A1 CA 3068363A1

Authority

CA

Canada

Prior art keywords

damaged

cells

antagonist

senescent cells

interaction

Prior art date

2017-06-29

Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)

Pending

Links

• Espacenet
• Global Dossier
• CIPO
• Discuss

• 230000008030 elimination Effects 0.000 title description 13
• 238000003379 elimination reaction Methods 0.000 title description 13
• 108700030875 Programmed Cell Death 1 Ligand 2 Proteins 0.000 claims abstract description 269
• 102100024213 Programmed cell death 1 ligand 2 Human genes 0.000 claims abstract description 264
• 238000000034 method Methods 0.000 claims abstract description 145
• 239000005557 antagonist Substances 0.000 claims abstract description 109
• 101710089372 Programmed cell death protein 1 Proteins 0.000 claims abstract description 103
• 102100040678 Programmed cell death protein 1 Human genes 0.000 claims abstract description 102
• 230000003993 interaction Effects 0.000 claims abstract description 61
• 230000014509 gene expression Effects 0.000 claims abstract description 36
• 230000032683 aging Effects 0.000 claims abstract description 21
• 108020004999 messenger RNA Proteins 0.000 claims description 68
• 108090000623 proteins and genes Proteins 0.000 claims description 62
• 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 61
• 206010028980 Neoplasm Diseases 0.000 claims description 59
• 201000010099 disease Diseases 0.000 claims description 57
• 238000011282 treatment Methods 0.000 claims description 55
• 101100407308 Mus musculus Pdcd1lg2 gene Proteins 0.000 claims description 46
• 102000004169 proteins and genes Human genes 0.000 claims description 45
• 239000000523 sample Substances 0.000 claims description 40
• 230000009758 senescence Effects 0.000 claims description 33
• 239000003814 drug Substances 0.000 claims description 30
• 239000000556 agonist Substances 0.000 claims description 29
• 239000000427 antigen Substances 0.000 claims description 29
• 108091007433 antigens Proteins 0.000 claims description 29
• 102000036639 antigens Human genes 0.000 claims description 29
• 239000000203 mixture Substances 0.000 claims description 29
• 201000011510 cancer Diseases 0.000 claims description 27
• 238000001514 detection method Methods 0.000 claims description 27
• 229940079593 drug Drugs 0.000 claims description 24
• 239000012634 fragment Substances 0.000 claims description 23
• 230000001965 increasing effect Effects 0.000 claims description 21
• 230000005855 radiation Effects 0.000 claims description 21
• 238000011529 RT qPCR Methods 0.000 claims description 20
• 230000003176 fibrotic effect Effects 0.000 claims description 18
• 238000002512 chemotherapy Methods 0.000 claims description 17
• 150000001875 compounds Chemical class 0.000 claims description 17
• 239000002872 contrast media Substances 0.000 claims description 17
• 230000001225 therapeutic effect Effects 0.000 claims description 17
• 108090000765 processed proteins & peptides Proteins 0.000 claims description 15
• 208000005069 pulmonary fibrosis Diseases 0.000 claims description 13
• 206010016654 Fibrosis Diseases 0.000 claims description 12
• 206010023421 Kidney fibrosis Diseases 0.000 claims description 12
• 230000004761 fibrosis Effects 0.000 claims description 12
• 239000012472 biological sample Substances 0.000 claims description 10
• 230000001939 inductive effect Effects 0.000 claims description 10
• 230000008569 process Effects 0.000 claims description 10
• 108091034117 Oligonucleotide Proteins 0.000 claims description 9
• 238000001959 radiotherapy Methods 0.000 claims description 9
• 238000002591 computed tomography Methods 0.000 claims description 8
• 230000009327 senolytic effect Effects 0.000 claims description 8
• 208000010412 Glaucoma Diseases 0.000 claims description 7
• 210000004556 brain Anatomy 0.000 claims description 7
• 208000025500 Hutchinson-Gilford progeria syndrome Diseases 0.000 claims description 6
• 206010061246 Intervertebral disc degeneration Diseases 0.000 claims description 6
• 208000007932 Progeria Diseases 0.000 claims description 6
• 201000011032 Werner Syndrome Diseases 0.000 claims description 6
• 230000000798 anti-retroviral effect Effects 0.000 claims description 6
• 239000003153 chemical reaction reagent Substances 0.000 claims description 6
• 238000002595 magnetic resonance imaging Methods 0.000 claims description 6
• 208000011580 syndromic disease Diseases 0.000 claims description 6
• 201000001320 Atherosclerosis Diseases 0.000 claims description 5
• 102000000536 PPAR gamma Human genes 0.000 claims description 5
• 108010016731 PPAR gamma Proteins 0.000 claims description 5
• JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 claims description 5
• 230000009368 gene silencing by RNA Effects 0.000 claims description 5
• 230000001575 pathological effect Effects 0.000 claims description 5
• 150000003384 small molecules Chemical class 0.000 claims description 5
• 208000001072 type 2 diabetes mellitus Diseases 0.000 claims description 5
• 208000002177 Cataract Diseases 0.000 claims description 4
• 201000003883 Cystic fibrosis Diseases 0.000 claims description 4
• 208000004196 Heart Aneurysm Diseases 0.000 claims description 4
• 201000008450 Intracranial aneurysm Diseases 0.000 claims description 4
• 208000008589 Obesity Diseases 0.000 claims description 4
• 108091030071 RNAI Proteins 0.000 claims description 4
• 208000027418 Wounds and injury Diseases 0.000 claims description 4
• 230000008049 biological aging Effects 0.000 claims description 4
• 230000001684 chronic effect Effects 0.000 claims description 4
• 208000019425 cirrhosis of liver Diseases 0.000 claims description 4
• 239000002537 cosmetic Substances 0.000 claims description 4
• 230000007850 degeneration Effects 0.000 claims description 4
• 230000006872 improvement Effects 0.000 claims description 4
• 230000000968 intestinal effect Effects 0.000 claims description 4
• 230000003902 lesion Effects 0.000 claims description 4
• 208000015122 neurodegenerative disease Diseases 0.000 claims description 4
• 235000020824 obesity Nutrition 0.000 claims description 4
• 201000008482 osteoarthritis Diseases 0.000 claims description 4
• 238000004393 prognosis Methods 0.000 claims description 4
• 208000001076 sarcopenia Diseases 0.000 claims description 4
• 208000003265 stomatitis Diseases 0.000 claims description 4
• 208000024827 Alzheimer disease Diseases 0.000 claims description 3
• 208000032467 Aplastic anaemia Diseases 0.000 claims description 3
• 208000032544 Cicatrix Diseases 0.000 claims description 3
• 208000010200 Cockayne syndrome Diseases 0.000 claims description 3
• 206010062759 Congenital dyskeratosis Diseases 0.000 claims description 3
• 206010014561 Emphysema Diseases 0.000 claims description 3
• 206010061431 Glial scar Diseases 0.000 claims description 3
• 206010018341 Gliosis Diseases 0.000 claims description 3
• 201000009794 Idiopathic Pulmonary Fibrosis Diseases 0.000 claims description 3
• 208000007256 Nevus Diseases 0.000 claims description 3
• 208000018737 Parkinson disease Diseases 0.000 claims description 3
• 201000009594 Systemic Scleroderma Diseases 0.000 claims description 3
• 206010042953 Systemic sclerosis Diseases 0.000 claims description 3
• 208000031037 Wiedemann-Rautenstrauch syndrome Diseases 0.000 claims description 3
• 206010052428 Wound Diseases 0.000 claims description 3
• 210000000845 cartilage Anatomy 0.000 claims description 3
• RUZYUOTYCVRMRZ-UHFFFAOYSA-N doxazosin Chemical compound C1OC2=CC=CC=C2OC1C(=O)N(CC1)CCN1C1=NC(N)=C(C=C(C(OC)=C2)OC)C2=N1 RUZYUOTYCVRMRZ-UHFFFAOYSA-N 0.000 claims description 3
• 208000009356 dyskeratosis congenita Diseases 0.000 claims description 3
• 230000035876 healing Effects 0.000 claims description 3
• 208000036971 interstitial lung disease 2 Diseases 0.000 claims description 3
• 208000002780 macular degeneration Diseases 0.000 claims description 3
• 238000012634 optical imaging Methods 0.000 claims description 3
• 208000002815 pulmonary hypertension Diseases 0.000 claims description 3
• 231100000241 scar Toxicity 0.000 claims description 3
• 230000037387 scars Effects 0.000 claims description 3
• 238000002054 transplantation Methods 0.000 claims description 3
• 208000019693 Lung disease Diseases 0.000 claims 2
• 239000003112 inhibitor Substances 0.000 abstract description 17
• 230000007170 pathology Effects 0.000 abstract description 16
• 231100000614 poison Toxicity 0.000 abstract description 2
• 239000003440 toxic substance Substances 0.000 abstract description 2
• 210000004027 cell Anatomy 0.000 description 331
• 230000000694 effects Effects 0.000 description 54
• 241000282414 Homo sapiens Species 0.000 description 41
• 241000699670 Mus sp. Species 0.000 description 36
• 235000018102 proteins Nutrition 0.000 description 35
• 150000001413 amino acids Chemical group 0.000 description 26
• 239000003981 vehicle Substances 0.000 description 26
• AOJJSUZBOXZQNB-TZSSRYMLSA-N Doxorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 AOJJSUZBOXZQNB-TZSSRYMLSA-N 0.000 description 24
• AHJRHEGDXFFMBM-UHFFFAOYSA-N palbociclib Chemical compound N1=C2N(C3CCCC3)C(=O)C(C(=O)C)=C(C)C2=CN=C1NC(N=C1)=CC=C1N1CCNCC1 AHJRHEGDXFFMBM-UHFFFAOYSA-N 0.000 description 24
• 229960004390 palbociclib Drugs 0.000 description 22
• 230000003827 upregulation Effects 0.000 description 22
• 210000001519 tissue Anatomy 0.000 description 20
• 102000002464 Galactosidases Human genes 0.000 description 19
• 108010093031 Galactosidases Proteins 0.000 description 19
• 241000699666 Mus <mouse, genus> Species 0.000 description 19
• 210000001744 T-lymphocyte Anatomy 0.000 description 19
• 108010006654 Bleomycin Proteins 0.000 description 18
• 229960001561 bleomycin Drugs 0.000 description 18
• OYVAGSVQBOHSSS-UAPAGMARSA-O bleomycin A2 Chemical compound N([C@H](C(=O)N[C@H](C)[C@@H](O)[C@H](C)C(=O)N[C@@H]([C@H](O)C)C(=O)NCCC=1SC=C(N=1)C=1SC=C(N=1)C(=O)NCCC[S+](C)C)[C@@H](O[C@H]1[C@H]([C@@H](O)[C@H](O)[C@H](CO)O1)O[C@@H]1[C@H]([C@@H](OC(N)=O)[C@H](O)[C@@H](CO)O1)O)C=1N=CNC=1)C(=O)C1=NC([C@H](CC(N)=O)NC[C@H](N)C(N)=O)=NC(N)=C1C OYVAGSVQBOHSSS-UAPAGMARSA-O 0.000 description 18
• 238000001727 in vivo Methods 0.000 description 18
• 108091032973 (ribonucleotides)n+m Proteins 0.000 description 17
• 235000001014 amino acid Nutrition 0.000 description 17
• 229940024606 amino acid Drugs 0.000 description 17
• 210000004072 lung Anatomy 0.000 description 17
• 230000010094 cellular senescence Effects 0.000 description 16
• 241001465754 Metazoa Species 0.000 description 13
• 239000007788 liquid Substances 0.000 description 13
• 201000001441 melanoma Diseases 0.000 description 13
• 239000000243 solution Substances 0.000 description 13
• 230000000903 blocking effect Effects 0.000 description 12
• 229960004679 doxorubicin Drugs 0.000 description 12
• 238000010186 staining Methods 0.000 description 12
• 108700039887 Essential Genes Proteins 0.000 description 11
• WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 11
• 239000003795 chemical substances by application Substances 0.000 description 11
• 230000004044 response Effects 0.000 description 11
• 230000002441 reversible effect Effects 0.000 description 11
• 230000005778 DNA damage Effects 0.000 description 10
• 231100000277 DNA damage Toxicity 0.000 description 10
• 108060003951 Immunoglobulin Proteins 0.000 description 10
• 102000018358 immunoglobulin Human genes 0.000 description 10
• 210000003734 kidney Anatomy 0.000 description 10
• 230000004071 biological effect Effects 0.000 description 9
• 230000007423 decrease Effects 0.000 description 9
• 210000000987 immune system Anatomy 0.000 description 9
• 230000005764 inhibitory process Effects 0.000 description 9
• 210000000056 organ Anatomy 0.000 description 9
• 238000003757 reverse transcription PCR Methods 0.000 description 9
• 210000003491 skin Anatomy 0.000 description 9
• 238000002560 therapeutic procedure Methods 0.000 description 9
• 210000004881 tumor cell Anatomy 0.000 description 9
• 239000012163 TRI reagent Substances 0.000 description 8
• 238000009825 accumulation Methods 0.000 description 8
• 238000010171 animal model Methods 0.000 description 8
• 238000003556 assay Methods 0.000 description 8
• 230000001413 cellular effect Effects 0.000 description 8
• 238000006243 chemical reaction Methods 0.000 description 8
• 239000002299 complementary DNA Substances 0.000 description 8
• 231100000024 genotoxic Toxicity 0.000 description 8
• 230000001738 genotoxic effect Effects 0.000 description 8
• 238000000338 in vitro Methods 0.000 description 8
• 230000006698 induction Effects 0.000 description 8
• 230000008685 targeting Effects 0.000 description 8
• 208000017667 Chronic Disease Diseases 0.000 description 7
• 108091028043 Nucleic acid sequence Proteins 0.000 description 7
• 208000004608 Ureteral Obstruction Diseases 0.000 description 7
• 238000004458 analytical method Methods 0.000 description 7
• 230000037396 body weight Effects 0.000 description 7
• 230000005754 cellular signaling Effects 0.000 description 7
• 230000008859 change Effects 0.000 description 7
• 238000002474 experimental method Methods 0.000 description 7
• 230000002401 inhibitory effect Effects 0.000 description 7
• 239000000463 material Substances 0.000 description 7
• 239000000047 product Substances 0.000 description 7
• 108010025464 Cyclin-Dependent Kinase 4 Proteins 0.000 description 6
• 108010025468 Cyclin-Dependent Kinase 6 Proteins 0.000 description 6
• 102100036252 Cyclin-dependent kinase 4 Human genes 0.000 description 6
• 102100026804 Cyclin-dependent kinase 6 Human genes 0.000 description 6
• 101001117312 Homo sapiens Programmed cell death 1 ligand 2 Proteins 0.000 description 6
• 241000124008 Mammalia Species 0.000 description 6
• FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 6
• 208000000102 Squamous Cell Carcinoma of Head and Neck Diseases 0.000 description 6
• 238000013459 approach Methods 0.000 description 6
• 210000004369 blood Anatomy 0.000 description 6
• 239000008280 blood Substances 0.000 description 6
• 239000013068 control sample Substances 0.000 description 6
• 230000000875 corresponding effect Effects 0.000 description 6
• 230000006378 damage Effects 0.000 description 6
• 230000006870 function Effects 0.000 description 6
• 201000000459 head and neck squamous cell carcinoma Diseases 0.000 description 6
• 230000028993 immune response Effects 0.000 description 6
• 238000002347 injection Methods 0.000 description 6
• 239000007924 injection Substances 0.000 description 6
• 239000003446 ligand Substances 0.000 description 6
• 238000011275 oncology therapy Methods 0.000 description 6
• 102000005962 receptors Human genes 0.000 description 6
• 108020003175 receptors Proteins 0.000 description 6
• 230000001105 regulatory effect Effects 0.000 description 6
• 230000011664 signaling Effects 0.000 description 6
• 239000000725 suspension Substances 0.000 description 6
• 239000003826 tablet Substances 0.000 description 6
• 102100024216 Programmed cell death 1 ligand 1 Human genes 0.000 description 5
• 238000000692 Student's t-test Methods 0.000 description 5
• 102000002689 Toll-like receptor Human genes 0.000 description 5
• 108020000411 Toll-like receptor Proteins 0.000 description 5
• 102100033254 Tumor suppressor ARF Human genes 0.000 description 5
• 230000004913 activation Effects 0.000 description 5
• 210000000612 antigen-presenting cell Anatomy 0.000 description 5
• 239000002246 antineoplastic agent Substances 0.000 description 5
• 230000008901 benefit Effects 0.000 description 5
• 238000010804 cDNA synthesis Methods 0.000 description 5
• 210000002865 immune cell Anatomy 0.000 description 5
• 230000007246 mechanism Effects 0.000 description 5
• 230000001404 mediated effect Effects 0.000 description 5
• XZWYZXLIPXDOLR-UHFFFAOYSA-N metformin Chemical compound CN(C)C(=N)NC(N)=N XZWYZXLIPXDOLR-UHFFFAOYSA-N 0.000 description 5
• 229960003105 metformin Drugs 0.000 description 5
• 150000007523 nucleic acids Chemical class 0.000 description 5
• 239000002773 nucleotide Substances 0.000 description 5
• 125000003729 nucleotide group Chemical group 0.000 description 5
• 239000008194 pharmaceutical composition Substances 0.000 description 5
• 239000000843 powder Substances 0.000 description 5
• 102000004196 processed proteins & peptides Human genes 0.000 description 5
• 230000002829 reductive effect Effects 0.000 description 5
• 230000028617 response to DNA damage stimulus Effects 0.000 description 5
• 230000003248 secreting effect Effects 0.000 description 5
• QFJCIRLUMZQUOT-HPLJOQBZSA-N sirolimus Chemical compound C1C[C@@H](O)[C@H](OC)C[C@@H]1C[C@@H](C)[C@H]1OC(=O)[C@@H]2CCCCN2C(=O)C(=O)[C@](O)(O2)[C@H](C)CC[C@H]2C[C@H](OC)/C(C)=C/C=C/C=C/[C@@H](C)C[C@@H](C)C(=O)[C@H](OC)[C@H](O)/C(C)=C/[C@@H](C)C(=O)C1 QFJCIRLUMZQUOT-HPLJOQBZSA-N 0.000 description 5
• 239000007787 solid Substances 0.000 description 5
• 238000012353 t test Methods 0.000 description 5
• 238000001262 western blot Methods 0.000 description 5
• OPIFSICVWOWJMJ-AEOCFKNESA-N 5-bromo-4-chloro-3-indolyl beta-D-galactoside Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1OC1=CNC2=CC=C(Br)C(Cl)=C12 OPIFSICVWOWJMJ-AEOCFKNESA-N 0.000 description 4
• 238000011740 C57BL/6 mouse Methods 0.000 description 4
• 108090000695 Cytokines Proteins 0.000 description 4
• 102000004127 Cytokines Human genes 0.000 description 4
• 108020004414 DNA Proteins 0.000 description 4
• 102000004190 Enzymes Human genes 0.000 description 4
• 108090000790 Enzymes Proteins 0.000 description 4
• 102000008394 Immunoglobulin Fragments Human genes 0.000 description 4
• 108010021625 Immunoglobulin Fragments Proteins 0.000 description 4
• 108010002350 Interleukin-2 Proteins 0.000 description 4
• 108090001005 Interleukin-6 Proteins 0.000 description 4
• 230000006044 T cell activation Effects 0.000 description 4
• 102000006467 TATA-Box Binding Protein Human genes 0.000 description 4
• 108010044281 TATA-Box Binding Protein Proteins 0.000 description 4
• 239000013543 active substance Substances 0.000 description 4
• 238000001574 biopsy Methods 0.000 description 4
• 239000000872 buffer Substances 0.000 description 4
• 230000005779 cell damage Effects 0.000 description 4
• 229940127089 cytotoxic agent Drugs 0.000 description 4
• 210000004443 dendritic cell Anatomy 0.000 description 4
• 238000003745 diagnosis Methods 0.000 description 4
• 208000035475 disorder Diseases 0.000 description 4
• 239000012636 effector Substances 0.000 description 4
• 239000000499 gel Substances 0.000 description 4
• 102000006602 glyceraldehyde-3-phosphate dehydrogenase Human genes 0.000 description 4
• 108020004445 glyceraldehyde-3-phosphate dehydrogenase Proteins 0.000 description 4
• 230000005291 magnetic effect Effects 0.000 description 4
• 239000011159 matrix material Substances 0.000 description 4
• 230000003287 optical effect Effects 0.000 description 4
• -1 oxide or alloy Chemical class 0.000 description 4
• 238000007911 parenteral administration Methods 0.000 description 4
• ZAHRKKWIAAJSAO-UHFFFAOYSA-N rapamycin Natural products COCC(O)C(=C/C(C)C(=O)CC(OC(=O)C1CCCCN1C(=O)C(=O)C2(O)OC(CC(OC)C(=CC=CC=CC(C)CC(C)C(=O)C)C)CCC2C)C(C)CC3CCC(O)C(C3)OC)C ZAHRKKWIAAJSAO-UHFFFAOYSA-N 0.000 description 4
• 238000011160 research Methods 0.000 description 4
• 229940080817 rotenone Drugs 0.000 description 4
• JUVIOZPCNVVQFO-UHFFFAOYSA-N rotenone Natural products O1C2=C3CC(C(C)=C)OC3=CC=C2C(=O)C2C1COC1=C2C=C(OC)C(OC)=C1 JUVIOZPCNVVQFO-UHFFFAOYSA-N 0.000 description 4
• 229960002930 sirolimus Drugs 0.000 description 4
• 239000011780 sodium chloride Substances 0.000 description 4
• 239000000126 substance Substances 0.000 description 4
• 208000024891 symptom Diseases 0.000 description 4
• 210000002700 urine Anatomy 0.000 description 4
• XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 4
• FWBHETKCLVMNFS-UHFFFAOYSA-N 4',6-Diamino-2-phenylindol Chemical compound C1=CC(C(=N)N)=CC=C1C1=CC2=CC=C(C(N)=N)C=C2N1 FWBHETKCLVMNFS-UHFFFAOYSA-N 0.000 description 3
• 108010074708 B7-H1 Antigen Proteins 0.000 description 3
• SXRSQZLOMIGNAQ-UHFFFAOYSA-N Glutaraldehyde Chemical compound O=CCCCC=O SXRSQZLOMIGNAQ-UHFFFAOYSA-N 0.000 description 3
• 241000282412 Homo Species 0.000 description 3
• 101000904691 Homo sapiens Bcl-2-like protein 2 Proteins 0.000 description 3
• 102000037982 Immune checkpoint proteins Human genes 0.000 description 3
• 108091008036 Immune checkpoint proteins Proteins 0.000 description 3
• 206010027476 Metastases Diseases 0.000 description 3
• 206010061309 Neoplasm progression Diseases 0.000 description 3
• 229940121678 PD-L2 antagonist Drugs 0.000 description 3
• 102000043850 Programmed Cell Death 1 Ligand 2 Human genes 0.000 description 3
• 108020004459 Small interfering RNA Proteins 0.000 description 3
• 230000006907 apoptotic process Effects 0.000 description 3
• 239000000090 biomarker Substances 0.000 description 3
• 239000002775 capsule Substances 0.000 description 3
• 210000001175 cerebrospinal fluid Anatomy 0.000 description 3
• 230000000295 complement effect Effects 0.000 description 3
• 239000006071 cream Substances 0.000 description 3
• 230000001461 cytolytic effect Effects 0.000 description 3
• 230000001472 cytotoxic effect Effects 0.000 description 3
• 239000000284 extract Substances 0.000 description 3
• 239000012530 fluid Substances 0.000 description 3
• 239000008187 granular material Substances 0.000 description 3
• 230000012010 growth Effects 0.000 description 3
• 102000048119 human PDCD1LG2 Human genes 0.000 description 3
• 230000006058 immune tolerance Effects 0.000 description 3
• 230000001506 immunosuppresive effect Effects 0.000 description 3
• 238000001802 infusion Methods 0.000 description 3
• 210000004185 liver Anatomy 0.000 description 3
• 230000002132 lysosomal effect Effects 0.000 description 3
• 239000003550 marker Substances 0.000 description 3
• 239000012528 membrane Substances 0.000 description 3
• 230000009401 metastasis Effects 0.000 description 3
• 210000003098 myoblast Anatomy 0.000 description 3
• 210000000822 natural killer cell Anatomy 0.000 description 3
• JLYAXFNOILIKPP-KXQOOQHDSA-N navitoclax Chemical compound C([C@@H](NC1=CC=C(C=C1S(=O)(=O)C(F)(F)F)S(=O)(=O)NC(=O)C1=CC=C(C=C1)N1CCN(CC1)CC1=C(CCC(C1)(C)C)C=1C=CC(Cl)=CC=1)CSC=1C=CC=CC=1)CN1CCOCC1 JLYAXFNOILIKPP-KXQOOQHDSA-N 0.000 description 3
• 239000003921 oil Substances 0.000 description 3
• 235000019198 oils Nutrition 0.000 description 3
• 238000003305 oral gavage Methods 0.000 description 3
• 230000002018 overexpression Effects 0.000 description 3
• 229940115272 polyinosinic:polycytidylic acid Drugs 0.000 description 3
• 230000003389 potentiating effect Effects 0.000 description 3
• 238000012552 review Methods 0.000 description 3
• 210000003296 saliva Anatomy 0.000 description 3
• 239000012192 staining solution Substances 0.000 description 3
• 239000008174 sterile solution Substances 0.000 description 3
• 239000000375 suspending agent Substances 0.000 description 3
• OEDPHAKKZGDBEV-GFPBKZJXSA-N (2s)-6-amino-2-[[(2s)-6-amino-2-[[(2s)-6-amino-2-[[(2s)-6-amino-2-[[(2s)-2-[[(2r)-3-[2,3-di(hexadecanoyloxy)propylsulfanyl]-2-(hexadecanoylamino)propanoyl]amino]-3-hydroxypropanoyl]amino]hexanoyl]amino]hexanoyl]amino]hexanoyl]amino]hexanoic acid Chemical compound NCCCC[C@@H](C(O)=O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)CCCCCCCCCCCCCCC)CSCC(COC(=O)CCCCCCCCCCCCCCC)OC(=O)CCCCCCCCCCCCCCC OEDPHAKKZGDBEV-GFPBKZJXSA-N 0.000 description 2
• 102000007469 Actins Human genes 0.000 description 2
• 108010085238 Actins Proteins 0.000 description 2
• ZAINTDRBUHCDPZ-UHFFFAOYSA-M Alexa Fluor 546 Chemical compound [H+].[Na+].CC1CC(C)(C)NC(C(=C2OC3=C(C4=NC(C)(C)CC(C)C4=CC3=3)S([O-])(=O)=O)S([O-])(=O)=O)=C1C=C2C=3C(C(=C(Cl)C=1Cl)C(O)=O)=C(Cl)C=1SCC(=O)NCCCCCC(=O)ON1C(=O)CCC1=O ZAINTDRBUHCDPZ-UHFFFAOYSA-M 0.000 description 2
• 102100023932 Bcl-2-like protein 2 Human genes 0.000 description 2
• 108091003079 Bovine Serum Albumin Proteins 0.000 description 2
• 206010006187 Breast cancer Diseases 0.000 description 2
• 208000026310 Breast neoplasm Diseases 0.000 description 2
• 208000005623 Carcinogenesis Diseases 0.000 description 2
• 108020004705 Codon Proteins 0.000 description 2
• 241000275449 Diplectrum formosum Species 0.000 description 2
• 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 2
• 238000002965 ELISA Methods 0.000 description 2
• 206010073306 Exposure to radiation Diseases 0.000 description 2
• 229910052688 Gadolinium Inorganic materials 0.000 description 2
• 108010010803 Gelatin Proteins 0.000 description 2
• DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 2
• 108010043121 Green Fluorescent Proteins Proteins 0.000 description 2
• 102000004144 Green Fluorescent Proteins Human genes 0.000 description 2
• 101000611936 Homo sapiens Programmed cell death protein 1 Proteins 0.000 description 2
• 101000763579 Homo sapiens Toll-like receptor 1 Proteins 0.000 description 2
• 101000831496 Homo sapiens Toll-like receptor 3 Proteins 0.000 description 2
• 108010001336 Horseradish Peroxidase Proteins 0.000 description 2
• 101001057751 Human cytomegalovirus (strain AD169) Uncharacterized protein IRL5 Proteins 0.000 description 2
• 101001057748 Human cytomegalovirus (strain AD169) Uncharacterized protein IRL7 Proteins 0.000 description 2
• 206010020880 Hypertrophy Diseases 0.000 description 2
• 102000017727 Immunoglobulin Variable Region Human genes 0.000 description 2
• 108010067060 Immunoglobulin Variable Region Proteins 0.000 description 2
• XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 description 2
• 229940083338 MDM2 inhibitor Drugs 0.000 description 2
• 239000012819 MDM2-Inhibitor Substances 0.000 description 2
• 108700018351 Major Histocompatibility Complex Proteins 0.000 description 2
• 101100452374 Mus musculus Ikbke gene Proteins 0.000 description 2
• PXHVJJICTQNCMI-UHFFFAOYSA-N Nickel Chemical compound [Ni] PXHVJJICTQNCMI-UHFFFAOYSA-N 0.000 description 2
• 108091007960 PI3Ks Proteins 0.000 description 2
• 108090000430 Phosphatidylinositol 3-kinases Proteins 0.000 description 2
• 102000003993 Phosphatidylinositol 3-kinases Human genes 0.000 description 2
• 108010047620 Phytohemagglutinins Proteins 0.000 description 2
• LCTONWCANYUPML-UHFFFAOYSA-M Pyruvate Chemical compound CC(=O)C([O-])=O LCTONWCANYUPML-UHFFFAOYSA-M 0.000 description 2
• REFJWTPEDVJJIY-UHFFFAOYSA-N Quercetin Chemical compound C=1C(O)=CC(O)=C(C(C=2O)=O)C=1OC=2C1=CC=C(O)C(O)=C1 REFJWTPEDVJJIY-UHFFFAOYSA-N 0.000 description 2
• 108020004511 Recombinant DNA Proteins 0.000 description 2
• 208000007660 Residual Neoplasm Diseases 0.000 description 2
• YASAKCUCGLMORW-UHFFFAOYSA-N Rosiglitazone Chemical compound C=1C=CC=NC=1N(C)CCOC(C=C1)=CC=C1CC1SC(=O)NC1=O YASAKCUCGLMORW-UHFFFAOYSA-N 0.000 description 2
• 229940124639 Selective inhibitor Drugs 0.000 description 2
• 108091008874 T cell receptors Proteins 0.000 description 2
• 102000016266 T-Cell Antigen Receptors Human genes 0.000 description 2
• 102000013530 TOR Serine-Threonine Kinases Human genes 0.000 description 2
• 108010065917 TOR Serine-Threonine Kinases Proteins 0.000 description 2
• 102100027010 Toll-like receptor 1 Human genes 0.000 description 2
• 102100024324 Toll-like receptor 3 Human genes 0.000 description 2
• 101710179195 Uncharacterized protein IRL6 Proteins 0.000 description 2
• 239000002313 adhesive film Substances 0.000 description 2
• 230000003679 aging effect Effects 0.000 description 2
• 150000001298 alcohols Chemical class 0.000 description 2
• 229940124650 anti-cancer therapies Drugs 0.000 description 2
• 230000000259 anti-tumor effect Effects 0.000 description 2
• 239000000611 antibody drug conjugate Substances 0.000 description 2
• 229940049595 antibody-drug conjugate Drugs 0.000 description 2
• 238000011319 anticancer therapy Methods 0.000 description 2
• 230000005735 apoptotic response Effects 0.000 description 2
• 230000005784 autoimmunity Effects 0.000 description 2
• 210000003719 b-lymphocyte Anatomy 0.000 description 2
• 230000033228 biological regulation Effects 0.000 description 2
• 238000010805 cDNA synthesis kit Methods 0.000 description 2
• 238000004364 calculation method Methods 0.000 description 2
• 230000036952 cancer formation Effects 0.000 description 2
• 238000002619 cancer immunotherapy Methods 0.000 description 2
• 231100000504 carcinogenesis Toxicity 0.000 description 2
• 238000004113 cell culture Methods 0.000 description 2
• 230000025084 cell cycle arrest Effects 0.000 description 2
• 230000030833 cell death Effects 0.000 description 2
• 230000004663 cell proliferation Effects 0.000 description 2
• 239000001913 cellulose Substances 0.000 description 2
• 229920002678 cellulose Polymers 0.000 description 2
• 235000010980 cellulose Nutrition 0.000 description 2
• 208000037976 chronic inflammation Diseases 0.000 description 2
• 230000006020 chronic inflammation Effects 0.000 description 2
• 238000007906 compression Methods 0.000 description 2
• 230000006835 compression Effects 0.000 description 2
• 230000004940 costimulation Effects 0.000 description 2
• 231100000433 cytotoxic Toxicity 0.000 description 2
• 230000003111 delayed effect Effects 0.000 description 2
• 238000013461 design Methods 0.000 description 2
• 229960003957 dexamethasone Drugs 0.000 description 2
• UREBDLICKHMUKA-CXSFZGCWSA-N dexamethasone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@@H](C)[C@@](C(=O)CO)(O)[C@@]1(C)C[C@@H]2O UREBDLICKHMUKA-CXSFZGCWSA-N 0.000 description 2
• 238000002405 diagnostic procedure Methods 0.000 description 2
• 239000003937 drug carrier Substances 0.000 description 2
• 239000000975 dye Substances 0.000 description 2
• 230000004064 dysfunction Effects 0.000 description 2
• 239000000839 emulsion Substances 0.000 description 2
• 238000010195 expression analysis Methods 0.000 description 2
• 239000013604 expression vector Substances 0.000 description 2
• 239000012091 fetal bovine serum Substances 0.000 description 2
• 239000000796 flavoring agent Substances 0.000 description 2
• 235000013355 food flavoring agent Nutrition 0.000 description 2
• 235000003599 food sweetener Nutrition 0.000 description 2
• 108020001507 fusion proteins Proteins 0.000 description 2
• 102000037865 fusion proteins Human genes 0.000 description 2
• UIWYJDYFSGRHKR-UHFFFAOYSA-N gadolinium atom Chemical compound [Gd] UIWYJDYFSGRHKR-UHFFFAOYSA-N 0.000 description 2
• 239000008273 gelatin Substances 0.000 description 2
• 229920000159 gelatin Polymers 0.000 description 2
• 235000019322 gelatine Nutrition 0.000 description 2
• 235000011852 gelatine desserts Nutrition 0.000 description 2
• 238000003197 gene knockdown Methods 0.000 description 2
• 239000011521 glass Substances 0.000 description 2
• PCHJSUWPFVWCPO-UHFFFAOYSA-N gold Chemical compound [Au] PCHJSUWPFVWCPO-UHFFFAOYSA-N 0.000 description 2
• 229910052737 gold Inorganic materials 0.000 description 2
• 239000010931 gold Substances 0.000 description 2
• 239000005090 green fluorescent protein Substances 0.000 description 2
• 230000036541 health Effects 0.000 description 2
• 210000003958 hematopoietic stem cell Anatomy 0.000 description 2
• 210000004408 hybridoma Anatomy 0.000 description 2
• JYGXADMDTFJGBT-VWUMJDOOSA-N hydrocortisone Chemical compound O=C1CC[C@]2(C)[C@H]3[C@@H](O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 JYGXADMDTFJGBT-VWUMJDOOSA-N 0.000 description 2
• 230000002209 hydrophobic effect Effects 0.000 description 2
• 230000002163 immunogen Effects 0.000 description 2
• 229940072221 immunoglobulins Drugs 0.000 description 2
• 238000003364 immunohistochemistry Methods 0.000 description 2
• 239000000411 inducer Substances 0.000 description 2
• 108091008042 inhibitory receptors Proteins 0.000 description 2
• 238000001990 intravenous administration Methods 0.000 description 2
• SZVJSHCCFOBDDC-UHFFFAOYSA-N iron(II,III) oxide Inorganic materials O=[Fe]O[Fe]O[Fe]=O SZVJSHCCFOBDDC-UHFFFAOYSA-N 0.000 description 2
• 210000002540 macrophage Anatomy 0.000 description 2
• HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
• 238000004519 manufacturing process Methods 0.000 description 2
• 238000005259 measurement Methods 0.000 description 2
• 210000004379 membrane Anatomy 0.000 description 2
• 238000010172 mouse model Methods 0.000 description 2
• DAZSWUUAFHBCGE-KRWDZBQOSA-N n-[(2s)-3-methyl-1-oxo-1-pyrrolidin-1-ylbutan-2-yl]-3-phenylpropanamide Chemical compound N([C@@H](C(C)C)C(=O)N1CCCC1)C(=O)CCC1=CC=CC=C1 DAZSWUUAFHBCGE-KRWDZBQOSA-N 0.000 description 2
• 229950004847 navitoclax Drugs 0.000 description 2
• NQDJXKOVJZTUJA-UHFFFAOYSA-N nevirapine Chemical compound C12=NC=CC=C2C(=O)NC=2C(C)=CC=NC=2N1C1CC1 NQDJXKOVJZTUJA-UHFFFAOYSA-N 0.000 description 2
• 208000002154 non-small cell lung carcinoma Diseases 0.000 description 2
• 102000039446 nucleic acids Human genes 0.000 description 2
• 108020004707 nucleic acids Proteins 0.000 description 2
• 210000004940 nucleus Anatomy 0.000 description 2
• 239000002674 ointment Substances 0.000 description 2
• 230000037361 pathway Effects 0.000 description 2
• 230000001885 phytohemagglutinin Effects 0.000 description 2
• HYAFETHFCAUJAY-UHFFFAOYSA-N pioglitazone Chemical compound N1=CC(CC)=CC=C1CCOC(C=C1)=CC=C1CC1C(=O)NC(=O)S1 HYAFETHFCAUJAY-UHFFFAOYSA-N 0.000 description 2
• 229920001184 polypeptide Polymers 0.000 description 2
• 239000003755 preservative agent Substances 0.000 description 2
• 230000002265 prevention Effects 0.000 description 2
• 239000003531 protein hydrolysate Substances 0.000 description 2
• 238000003762 quantitative reverse transcription PCR Methods 0.000 description 2
• 239000003642 reactive oxygen metabolite Substances 0.000 description 2
• 238000003753 real-time PCR Methods 0.000 description 2
• 201000002793 renal fibrosis Diseases 0.000 description 2
• 239000004576 sand Substances 0.000 description 2
• 230000028327 secretion Effects 0.000 description 2
• 229940125381 senolytic agent Drugs 0.000 description 2
• 238000002864 sequence alignment Methods 0.000 description 2
• 238000009097 single-agent therapy Methods 0.000 description 2
• 239000008247 solid mixture Substances 0.000 description 2
• 239000002904 solvent Substances 0.000 description 2
• 241000894007 species Species 0.000 description 2
• 230000035882 stress Effects 0.000 description 2
• 238000007920 subcutaneous administration Methods 0.000 description 2
• 238000006467 substitution reaction Methods 0.000 description 2
• 230000020382 suppression by virus of host antigen processing and presentation of peptide antigen via MHC class I Effects 0.000 description 2
• 239000003765 sweetening agent Substances 0.000 description 2
• 239000006188 syrup Substances 0.000 description 2
• 235000020357 syrup Nutrition 0.000 description 2
• 229940044655 toll-like receptor 9 agonist Drugs 0.000 description 2
• 230000002103 transcriptional effect Effects 0.000 description 2
• 208000029729 tumor suppressor gene on chromosome 11 Diseases 0.000 description 2
• 230000000007 visual effect Effects 0.000 description 2
• MTCFGRXMJLQNBG-REOHCLBHSA-N (2S)-2-Amino-3-hydroxypropansäure Chemical compound OC[C@H](N)C(O)=O MTCFGRXMJLQNBG-REOHCLBHSA-N 0.000 description 1
• JNYAEWCLZODPBN-JGWLITMVSA-N (2r,3r,4s)-2-[(1r)-1,2-dihydroxyethyl]oxolane-3,4-diol Chemical compound OC[C@@H](O)[C@H]1OC[C@H](O)[C@H]1O JNYAEWCLZODPBN-JGWLITMVSA-N 0.000 description 1
• DOEWDSDBFRHVAP-KRXBUXKQSA-N (E)-3-tosylacrylonitrile Chemical compound CC1=CC=C(S(=O)(=O)\C=C\C#N)C=C1 DOEWDSDBFRHVAP-KRXBUXKQSA-N 0.000 description 1
• ZESRJSPZRDMNHY-YFWFAHHUSA-N 11-deoxycorticosterone Chemical compound O=C1CC[C@]2(C)[C@H]3CC[C@](C)([C@H](CC4)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 ZESRJSPZRDMNHY-YFWFAHHUSA-N 0.000 description 1
• HVCOBJNICQPDBP-UHFFFAOYSA-N 3-[3-[3,5-dihydroxy-6-methyl-4-(3,4,5-trihydroxy-6-methyloxan-2-yl)oxyoxan-2-yl]oxydecanoyloxy]decanoic acid;hydrate Chemical compound O.OC1C(OC(CC(=O)OC(CCCCCCC)CC(O)=O)CCCCCCC)OC(C)C(O)C1OC1C(O)C(O)C(O)C(C)O1 HVCOBJNICQPDBP-UHFFFAOYSA-N 0.000 description 1
• CYDQOEWLBCCFJZ-UHFFFAOYSA-N 4-(4-fluorophenyl)oxane-4-carboxylic acid Chemical compound C=1C=C(F)C=CC=1C1(C(=O)O)CCOCC1 CYDQOEWLBCCFJZ-UHFFFAOYSA-N 0.000 description 1
• IBPVXAOOVUAOKJ-UHFFFAOYSA-N 4-[[2,6-difluoro-4-[3-(1-piperidin-4-ylpyrazol-4-yl)quinoxalin-5-yl]phenyl]methyl]morpholine Chemical compound FC1=CC(C=2C3=NC(=CN=C3C=CC=2)C2=CN(N=C2)C2CCNCC2)=CC(F)=C1CN1CCOCC1 IBPVXAOOVUAOKJ-UHFFFAOYSA-N 0.000 description 1
• HIQIXEFWDLTDED-UHFFFAOYSA-N 4-hydroxy-1-piperidin-4-ylpyrrolidin-2-one Chemical compound O=C1CC(O)CN1C1CCNCC1 HIQIXEFWDLTDED-UHFFFAOYSA-N 0.000 description 1
• NMUSYJAQQFHJEW-KVTDHHQDSA-N 5-azacytidine Chemical compound O=C1N=C(N)N=CN1[C@H]1[C@H](O)[C@H](O)[C@@H](CO)O1 NMUSYJAQQFHJEW-KVTDHHQDSA-N 0.000 description 1
• RHXHGRAEPCAFML-UHFFFAOYSA-N 7-cyclopentyl-n,n-dimethyl-2-[(5-piperazin-1-ylpyridin-2-yl)amino]pyrrolo[2,3-d]pyrimidine-6-carboxamide Chemical compound N1=C2N(C3CCCC3)C(C(=O)N(C)C)=CC2=CN=C1NC(N=C1)=CC=C1N1CCNCC1 RHXHGRAEPCAFML-UHFFFAOYSA-N 0.000 description 1
• ZCYVEMRRCGMTRW-UHFFFAOYSA-N 7553-56-2 Chemical compound [I] ZCYVEMRRCGMTRW-UHFFFAOYSA-N 0.000 description 1
• HPLNQCPCUACXLM-PGUFJCEWSA-N ABT-737 Chemical compound C([C@@H](CCN(C)C)NC=1C(=CC(=CC=1)S(=O)(=O)NC(=O)C=1C=CC(=CC=1)N1CCN(CC=2C(=CC=CC=2)C=2C=CC(Cl)=CC=2)CC1)[N+]([O-])=O)SC1=CC=CC=C1 HPLNQCPCUACXLM-PGUFJCEWSA-N 0.000 description 1
• 206010067484 Adverse reaction Diseases 0.000 description 1
• PQSUYGKTWSAVDQ-ZVIOFETBSA-N Aldosterone Chemical compound C([C@@]1([C@@H](C(=O)CO)CC[C@H]1[C@@H]1CC2)C=O)[C@H](O)[C@@H]1[C@]1(C)C2=CC(=O)CC1 PQSUYGKTWSAVDQ-ZVIOFETBSA-N 0.000 description 1
• PQSUYGKTWSAVDQ-UHFFFAOYSA-N Aldosterone Natural products C1CC2C3CCC(C(=O)CO)C3(C=O)CC(O)C2C2(C)C1=CC(=O)CC2 PQSUYGKTWSAVDQ-UHFFFAOYSA-N 0.000 description 1
• 102000002260 Alkaline Phosphatase Human genes 0.000 description 1
• 108020004774 Alkaline Phosphatase Proteins 0.000 description 1
• GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
• 235000003911 Arachis Nutrition 0.000 description 1
• 244000105624 Arachis hypogaea Species 0.000 description 1
• 239000004475 Arginine Substances 0.000 description 1
• DCXYFEDJOCDNAF-UHFFFAOYSA-N Asparagine Natural products OC(=O)C(N)CC(N)=O DCXYFEDJOCDNAF-UHFFFAOYSA-N 0.000 description 1
• 208000035143 Bacterial infection Diseases 0.000 description 1
• 241000283690 Bos taurus Species 0.000 description 1
• 210000001266 CD8-positive T-lymphocyte Anatomy 0.000 description 1
• 241000283707 Capra Species 0.000 description 1
• 206010007572 Cardiac hypertrophy Diseases 0.000 description 1
• 208000006029 Cardiomegaly Diseases 0.000 description 1
• 102000006435 Chemokine CCL21 Human genes 0.000 description 1
• 108010083702 Chemokine CCL21 Proteins 0.000 description 1
• 108010077544 Chromatin Proteins 0.000 description 1
• 208000006545 Chronic Obstructive Pulmonary Disease Diseases 0.000 description 1
• 108091026890 Coding region Proteins 0.000 description 1
• 102000008186 Collagen Human genes 0.000 description 1
• 108010035532 Collagen Proteins 0.000 description 1
• FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 1
• 101100447432 Danio rerio gapdh-2 gene Proteins 0.000 description 1
• ZBNZXTGUTAYRHI-UHFFFAOYSA-N Dasatinib Chemical compound C=1C(N2CCN(CCO)CC2)=NC(C)=NC=1NC(S1)=NC=C1C(=O)NC1=C(C)C=CC=C1Cl ZBNZXTGUTAYRHI-UHFFFAOYSA-N 0.000 description 1
• 206010011968 Decreased immune responsiveness Diseases 0.000 description 1
• 239000004375 Dextrin Substances 0.000 description 1
• 229920001353 Dextrin Polymers 0.000 description 1
• 229910052692 Dysprosium Inorganic materials 0.000 description 1
• XPOQHMRABVBWPR-UHFFFAOYSA-N Efavirenz Natural products O1C(=O)NC2=CC=C(Cl)C=C2C1(C(F)(F)F)C#CC1CC1 XPOQHMRABVBWPR-UHFFFAOYSA-N 0.000 description 1
• LVGKNOAMLMIIKO-UHFFFAOYSA-N Elaidinsaeure-aethylester Natural products CCCCCCCCC=CCCCCCCCC(=O)OCC LVGKNOAMLMIIKO-UHFFFAOYSA-N 0.000 description 1
• IAYPIBMASNFSPL-UHFFFAOYSA-N Ethylene oxide Chemical compound C1CO1 IAYPIBMASNFSPL-UHFFFAOYSA-N 0.000 description 1
• 108010037362 Extracellular Matrix Proteins Proteins 0.000 description 1
• 102000010834 Extracellular Matrix Proteins Human genes 0.000 description 1
• 108091006020 Fc-tagged proteins Proteins 0.000 description 1
• 208000036119 Frailty Diseases 0.000 description 1
• 239000005715 Fructose Substances 0.000 description 1
• 101150112014 Gapdh gene Proteins 0.000 description 1
• WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
• WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 description 1
• 239000004471 Glycine Substances 0.000 description 1
• 229930186217 Glycolipid Natural products 0.000 description 1
• 208000017891 HER2 positive breast carcinoma Diseases 0.000 description 1
• 101710088172 HTH-type transcriptional regulator RipA Proteins 0.000 description 1
• 101100407307 Homo sapiens PDCD1LG2 gene Proteins 0.000 description 1
• 101001117317 Homo sapiens Programmed cell death 1 ligand 1 Proteins 0.000 description 1
• 101000831567 Homo sapiens Toll-like receptor 2 Proteins 0.000 description 1
• 101000669447 Homo sapiens Toll-like receptor 4 Proteins 0.000 description 1
• 101000733249 Homo sapiens Tumor suppressor ARF Proteins 0.000 description 1
• 239000003458 I kappa b kinase inhibitor Substances 0.000 description 1
• 206010061218 Inflammation Diseases 0.000 description 1
• 206010022489 Insulin Resistance Diseases 0.000 description 1
• 102000042838 JAK family Human genes 0.000 description 1
• 108091082332 JAK family Proteins 0.000 description 1
• 229940121730 Janus kinase 2 inhibitor Drugs 0.000 description 1
• KJHKTHWMRKYKJE-SUGCFTRWSA-N Kaletra Chemical compound N1([C@@H](C(C)C)C(=O)N[C@H](C[C@H](O)[C@H](CC=2C=CC=CC=2)NC(=O)COC=2C(=CC=CC=2C)C)CC=2C=CC=CC=2)CCCNC1=O KJHKTHWMRKYKJE-SUGCFTRWSA-N 0.000 description 1
• XUJNEKJLAYXESH-REOHCLBHSA-N L-Cysteine Chemical compound SC[C@H](N)C(O)=O XUJNEKJLAYXESH-REOHCLBHSA-N 0.000 description 1
• ONIBWKKTOPOVIA-BYPYZUCNSA-N L-Proline Chemical compound OC(=O)[C@@H]1CCCN1 ONIBWKKTOPOVIA-BYPYZUCNSA-N 0.000 description 1
• QNAYBMKLOCPYGJ-REOHCLBHSA-N L-alanine Chemical compound C[C@H](N)C(O)=O QNAYBMKLOCPYGJ-REOHCLBHSA-N 0.000 description 1
• ODKSFYDXXFIFQN-BYPYZUCNSA-P L-argininium(2+) Chemical compound NC(=[NH2+])NCCC[C@H]([NH3+])C(O)=O ODKSFYDXXFIFQN-BYPYZUCNSA-P 0.000 description 1
• DCXYFEDJOCDNAF-REOHCLBHSA-N L-asparagine Chemical compound OC(=O)[C@@H](N)CC(N)=O DCXYFEDJOCDNAF-REOHCLBHSA-N 0.000 description 1
• CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 description 1
• WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 1
• ZDXPYRJPNDTMRX-VKHMYHEASA-N L-glutamine Chemical compound OC(=O)[C@@H](N)CCC(N)=O ZDXPYRJPNDTMRX-VKHMYHEASA-N 0.000 description 1
• HNDVDQJCIGZPNO-YFKPBYRVSA-N L-histidine Chemical compound OC(=O)[C@@H](N)CC1=CN=CN1 HNDVDQJCIGZPNO-YFKPBYRVSA-N 0.000 description 1
• AGPKZVBTJJNPAG-WHFBIAKZSA-N L-isoleucine Chemical compound CC[C@H](C)[C@H](N)C(O)=O AGPKZVBTJJNPAG-WHFBIAKZSA-N 0.000 description 1
• ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 description 1
• KDXKERNSBIXSRK-YFKPBYRVSA-N L-lysine Chemical compound NCCCC[C@H](N)C(O)=O KDXKERNSBIXSRK-YFKPBYRVSA-N 0.000 description 1
• FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical compound CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 description 1
• COLNVLDHVKWLRT-QMMMGPOBSA-N L-phenylalanine Chemical compound OC(=O)[C@@H](N)CC1=CC=CC=C1 COLNVLDHVKWLRT-QMMMGPOBSA-N 0.000 description 1
• AYFVYJQAPQTCCC-GBXIJSLDSA-N L-threonine Chemical compound C[C@@H](O)[C@H](N)C(O)=O AYFVYJQAPQTCCC-GBXIJSLDSA-N 0.000 description 1
• QIVBCDIJIAJPQS-VIFPVBQESA-N L-tryptophane Chemical compound C1=CC=C2C(C[C@H](N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-VIFPVBQESA-N 0.000 description 1
• OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 description 1
• KZSNJWFQEVHDMF-BYPYZUCNSA-N L-valine Chemical compound CC(C)[C@H](N)C(O)=O KZSNJWFQEVHDMF-BYPYZUCNSA-N 0.000 description 1
• 239000002067 L01XE06 - Dasatinib Substances 0.000 description 1
• GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
• 208000031671 Large B-Cell Diffuse Lymphoma Diseases 0.000 description 1
• 108090001090 Lectins Proteins 0.000 description 1
• 102000004856 Lectins Human genes 0.000 description 1
• 240000007472 Leucaena leucocephala Species 0.000 description 1
• 235000010643 Leucaena leucocephala Nutrition 0.000 description 1
• ROHFNLRQFUQHCH-UHFFFAOYSA-N Leucine Natural products CC(C)CC(N)C(O)=O ROHFNLRQFUQHCH-UHFFFAOYSA-N 0.000 description 1
• KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 1
• 239000004472 Lysine Substances 0.000 description 1
• 206010027480 Metastatic malignant melanoma Diseases 0.000 description 1
• 108700011259 MicroRNAs Proteins 0.000 description 1
• 101100519207 Mus musculus Pdcd1 gene Proteins 0.000 description 1
• 239000000020 Nitrocellulose Substances 0.000 description 1
• 101150064354 PDCD1LG2 gene Proteins 0.000 description 1
• 208000009077 Pigmented Nevus Diseases 0.000 description 1
• 241000276498 Pollachius virens Species 0.000 description 1
• 101710094000 Programmed cell death 1 ligand 1 Proteins 0.000 description 1
• ONIBWKKTOPOVIA-UHFFFAOYSA-N Proline Natural products OC(=O)C1CCCN1 ONIBWKKTOPOVIA-UHFFFAOYSA-N 0.000 description 1
• 206010060862 Prostate cancer Diseases 0.000 description 1
• 208000000236 Prostatic Neoplasms Diseases 0.000 description 1
• 102000003923 Protein Kinase C Human genes 0.000 description 1
• 108090000315 Protein Kinase C Proteins 0.000 description 1
• ZVOLCUVKHLEPEV-UHFFFAOYSA-N Quercetagetin Natural products C1=C(O)C(O)=CC=C1C1=C(O)C(=O)C2=C(O)C(O)=C(O)C=C2O1 ZVOLCUVKHLEPEV-UHFFFAOYSA-N 0.000 description 1
• 238000012228 RNA interference-mediated gene silencing Methods 0.000 description 1
• 241000700159 Rattus Species 0.000 description 1
• 230000010799 Receptor Interactions Effects 0.000 description 1
• 108700008625 Reporter Genes Proteins 0.000 description 1
• HWTZYBCRDDUBJY-UHFFFAOYSA-N Rhynchosin Natural products C1=C(O)C(O)=CC=C1C1=C(O)C(=O)C2=CC(O)=C(O)C=C2O1 HWTZYBCRDDUBJY-UHFFFAOYSA-N 0.000 description 1
• NCDNCNXCDXHOMX-UHFFFAOYSA-N Ritonavir Natural products C=1C=CC=CC=1CC(NC(=O)OCC=1SC=NC=1)C(O)CC(CC=1C=CC=CC=1)NC(=O)C(C(C)C)NC(=O)N(C)CC1=CSC(C(C)C)=N1 NCDNCNXCDXHOMX-UHFFFAOYSA-N 0.000 description 1
• 239000006146 Roswell Park Memorial Institute medium Substances 0.000 description 1
• MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 description 1
• 102100036077 Serine/threonine-protein kinase pim-1 Human genes 0.000 description 1
• 108091027967 Small hairpin RNA Proteins 0.000 description 1
• 229920002472 Starch Polymers 0.000 description 1
• XNKLLVCARDGLGL-JGVFFNPUSA-N Stavudine Chemical compound O=C1NC(=O)C(C)=CN1[C@H]1C=C[C@@H](CO)O1 XNKLLVCARDGLGL-JGVFFNPUSA-N 0.000 description 1
• 208000002847 Surgical Wound Diseases 0.000 description 1
• 229940123464 Thiazolidinedione Drugs 0.000 description 1
• FOCVUCIESVLUNU-UHFFFAOYSA-N Thiotepa Chemical compound C1CN1P(N1CC1)(=S)N1CC1 FOCVUCIESVLUNU-UHFFFAOYSA-N 0.000 description 1
• AYFVYJQAPQTCCC-UHFFFAOYSA-N Threonine Natural products CC(O)C(N)C(O)=O AYFVYJQAPQTCCC-UHFFFAOYSA-N 0.000 description 1
• 239000004473 Threonine Substances 0.000 description 1
• SUJUHGSWHZTSEU-UHFFFAOYSA-N Tipranavir Natural products C1C(O)=C(C(CC)C=2C=C(NS(=O)(=O)C=3N=CC(=CC=3)C(F)(F)F)C=CC=2)C(=O)OC1(CCC)CCC1=CC=CC=C1 SUJUHGSWHZTSEU-UHFFFAOYSA-N 0.000 description 1
• 102100024333 Toll-like receptor 2 Human genes 0.000 description 1
• 102100039360 Toll-like receptor 4 Human genes 0.000 description 1
• 239000007983 Tris buffer Substances 0.000 description 1
• QIVBCDIJIAJPQS-UHFFFAOYSA-N Tryptophan Natural products C1=CC=C2C(CC(N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-UHFFFAOYSA-N 0.000 description 1
• 102000044209 Tumor Suppressor Genes Human genes 0.000 description 1
• 108700025716 Tumor Suppressor Genes Proteins 0.000 description 1
• 102000015098 Tumor Suppressor Protein p53 Human genes 0.000 description 1
• 108010078814 Tumor Suppressor Protein p53 Proteins 0.000 description 1
• KZSNJWFQEVHDMF-UHFFFAOYSA-N Valine Natural products CC(C)C(N)C(O)=O KZSNJWFQEVHDMF-UHFFFAOYSA-N 0.000 description 1
• 241000251539 Vertebrata <Metazoa> Species 0.000 description 1
• 241000700605 Viruses Species 0.000 description 1
• WREGKURFCTUGRC-POYBYMJQSA-N Zalcitabine Chemical compound O=C1N=C(N)C=CN1[C@@H]1O[C@H](CO)CC1 WREGKURFCTUGRC-POYBYMJQSA-N 0.000 description 1
• 229960004748 abacavir Drugs 0.000 description 1
• MCGSCOLBFJQGHM-SCZZXKLOSA-N abacavir Chemical compound C=12N=CN([C@H]3C=C[C@@H](CO)C3)C2=NC(N)=NC=1NC1CC1 MCGSCOLBFJQGHM-SCZZXKLOSA-N 0.000 description 1
• 210000000683 abdominal cavity Anatomy 0.000 description 1
• 229950001573 abemaciclib Drugs 0.000 description 1
• 230000001594 aberrant effect Effects 0.000 description 1
• 230000002159 abnormal effect Effects 0.000 description 1
• DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 description 1
• 230000002378 acidificating effect Effects 0.000 description 1
• 230000003213 activating effect Effects 0.000 description 1
• 239000000654 additive Substances 0.000 description 1
• 230000011759 adipose tissue development Effects 0.000 description 1
• 230000002411 adverse Effects 0.000 description 1
• 230000006838 adverse reaction Effects 0.000 description 1
• 239000000443 aerosol Substances 0.000 description 1
• 238000001042 affinity chromatography Methods 0.000 description 1
• 235000004279 alanine Nutrition 0.000 description 1
• 229960002478 aldosterone Drugs 0.000 description 1
• 239000000956 alloy Substances 0.000 description 1
• 229910045601 alloy Inorganic materials 0.000 description 1
• 230000004075 alteration Effects 0.000 description 1
• 230000001668 ameliorated effect Effects 0.000 description 1
• 230000003321 amplification Effects 0.000 description 1
• 150000008064 anhydrides Chemical class 0.000 description 1
• 230000002424 anti-apoptotic effect Effects 0.000 description 1
• 230000000890 antigenic effect Effects 0.000 description 1
• ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 1
• 235000009582 asparagine Nutrition 0.000 description 1
• 229960001230 asparagine Drugs 0.000 description 1
• 235000003704 aspartic acid Nutrition 0.000 description 1
• 206010003549 asthenia Diseases 0.000 description 1
• 210000001130 astrocyte Anatomy 0.000 description 1
• 230000003143 atherosclerotic effect Effects 0.000 description 1
• 230000003305 autocrine Effects 0.000 description 1
• 229960002756 azacitidine Drugs 0.000 description 1
• 208000022362 bacterial infectious disease Diseases 0.000 description 1
• 239000011324 bead Substances 0.000 description 1
• 229960004495 beclometasone Drugs 0.000 description 1
• NBMKJKDGKREAPL-DVTGEIKXSA-N beclomethasone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(Cl)[C@@H]1[C@@H]1C[C@H](C)[C@@](C(=O)CO)(O)[C@@]1(C)C[C@@H]2O NBMKJKDGKREAPL-DVTGEIKXSA-N 0.000 description 1
• WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
• OQFSQFPPLPISGP-UHFFFAOYSA-N beta-carboxyaspartic acid Natural products OC(=O)C(N)C(C(O)=O)C(O)=O OQFSQFPPLPISGP-UHFFFAOYSA-N 0.000 description 1
• 239000003833 bile salt Substances 0.000 description 1
• 229940093761 bile salts Drugs 0.000 description 1
• 239000011230 binding agent Substances 0.000 description 1
• 239000013060 biological fluid Substances 0.000 description 1
• 239000002981 blocking agent Substances 0.000 description 1
• 210000004899 c-terminal region Anatomy 0.000 description 1
• 239000001506 calcium phosphate Substances 0.000 description 1
• 229910000389 calcium phosphate Inorganic materials 0.000 description 1
• 235000011010 calcium phosphates Nutrition 0.000 description 1
• 150000001720 carbohydrates Chemical class 0.000 description 1
• 235000014633 carbohydrates Nutrition 0.000 description 1
• JJWKPURADFRFRB-UHFFFAOYSA-N carbonyl sulfide Chemical compound O=C=S JJWKPURADFRFRB-UHFFFAOYSA-N 0.000 description 1
• 239000001768 carboxy methyl cellulose Substances 0.000 description 1
• 230000000747 cardiac effect Effects 0.000 description 1
• 230000009787 cardiac fibrosis Effects 0.000 description 1
• 210000003855 cell nucleus Anatomy 0.000 description 1
• 230000007969 cellular immunity Effects 0.000 description 1
• 230000004640 cellular pathway Effects 0.000 description 1
• 230000036755 cellular response Effects 0.000 description 1
• 238000012512 characterization method Methods 0.000 description 1
• 125000003636 chemical group Chemical group 0.000 description 1
• 229940044683 chemotherapy drug Drugs 0.000 description 1
• 208000011654 childhood malignant neoplasm Diseases 0.000 description 1
• 210000003483 chromatin Anatomy 0.000 description 1
• 210000000349 chromosome Anatomy 0.000 description 1
• 208000024207 chronic leukemia Diseases 0.000 description 1
• 238000005352 clarification Methods 0.000 description 1
• 238000000576 coating method Methods 0.000 description 1
• 229910017052 cobalt Inorganic materials 0.000 description 1
• 239000010941 cobalt Substances 0.000 description 1
• GUTLYIVDDKVIGB-UHFFFAOYSA-N cobalt atom Chemical compound [Co] GUTLYIVDDKVIGB-UHFFFAOYSA-N 0.000 description 1
• 235000019864 coconut oil Nutrition 0.000 description 1
• 239000003240 coconut oil Substances 0.000 description 1
• 229920001436 collagen Polymers 0.000 description 1
• 239000003086 colorant Substances 0.000 description 1
• 238000002648 combination therapy Methods 0.000 description 1
• 230000004154 complement system Effects 0.000 description 1
• 238000004624 confocal microscopy Methods 0.000 description 1
• 230000002596 correlated effect Effects 0.000 description 1
• 239000003246 corticosteroid Substances 0.000 description 1
• 229960001334 corticosteroids Drugs 0.000 description 1
• 230000000139 costimulatory effect Effects 0.000 description 1
• 210000004748 cultured cell Anatomy 0.000 description 1
• 238000011461 current therapy Methods 0.000 description 1
• XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 description 1
• 235000018417 cysteine Nutrition 0.000 description 1
• 230000016396 cytokine production Effects 0.000 description 1
• 238000011393 cytotoxic chemotherapy Methods 0.000 description 1
• 229960002448 dasatinib Drugs 0.000 description 1
• ZESRJSPZRDMNHY-UHFFFAOYSA-N de-oxy corticosterone Natural products O=C1CCC2(C)C3CCC(C)(C(CC4)C(=O)CO)C4C3CCC2=C1 ZESRJSPZRDMNHY-UHFFFAOYSA-N 0.000 description 1
• 230000034994 death Effects 0.000 description 1
• 230000002950 deficient Effects 0.000 description 1
• 208000018180 degenerative disc disease Diseases 0.000 description 1
• 230000003412 degenerative effect Effects 0.000 description 1
• 230000001934 delay Effects 0.000 description 1
• 230000002939 deleterious effect Effects 0.000 description 1
• 229960003964 deoxycholic acid Drugs 0.000 description 1
• 229940119740 deoxycorticosterone Drugs 0.000 description 1
• 230000001419 dependent effect Effects 0.000 description 1
• 230000008021 deposition Effects 0.000 description 1
• 230000001627 detrimental effect Effects 0.000 description 1
• 238000011161 development Methods 0.000 description 1
• 230000018109 developmental process Effects 0.000 description 1
• 235000019425 dextrin Nutrition 0.000 description 1
• 238000002059 diagnostic imaging Methods 0.000 description 1
• 235000005911 diet Nutrition 0.000 description 1
• 230000037213 diet Effects 0.000 description 1
• 206010012818 diffuse large B-cell lymphoma Diseases 0.000 description 1
• 229940042399 direct acting antivirals protease inhibitors Drugs 0.000 description 1
• 230000005782 double-strand break Effects 0.000 description 1
• KBQHZAAAGSGFKK-UHFFFAOYSA-N dysprosium atom Chemical compound [Dy] KBQHZAAAGSGFKK-UHFFFAOYSA-N 0.000 description 1
• 229960003804 efavirenz Drugs 0.000 description 1
• XPOQHMRABVBWPR-ZDUSSCGKSA-N efavirenz Chemical compound C([C@]1(C2=CC(Cl)=CC=C2NC(=O)O1)C(F)(F)F)#CC1CC1 XPOQHMRABVBWPR-ZDUSSCGKSA-N 0.000 description 1
• 239000003995 emulsifying agent Substances 0.000 description 1
• 210000002889 endothelial cell Anatomy 0.000 description 1
• 238000005516 engineering process Methods 0.000 description 1
• 231100001238 environmental toxicant Toxicity 0.000 description 1
• 230000002255 enzymatic effect Effects 0.000 description 1
• 230000001973 epigenetic effect Effects 0.000 description 1
• 150000002148 esters Chemical class 0.000 description 1
• LVGKNOAMLMIIKO-QXMHVHEDSA-N ethyl oleate Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OCC LVGKNOAMLMIIKO-QXMHVHEDSA-N 0.000 description 1
• 229940093471 ethyl oleate Drugs 0.000 description 1
• 230000017188 evasion or tolerance of host immune response Effects 0.000 description 1
• 230000005284 excitation Effects 0.000 description 1
• 239000003925 fat Substances 0.000 description 1
• 235000019197 fats Nutrition 0.000 description 1
• 210000002950 fibroblast Anatomy 0.000 description 1
• 239000000945 filler Substances 0.000 description 1
• 150000007946 flavonol Chemical class 0.000 description 1
• HVQAJTFOCKOKIN-UHFFFAOYSA-N flavonol Natural products O1C2=CC=CC=C2C(=O)C(O)=C1C1=CC=CC=C1 HVQAJTFOCKOKIN-UHFFFAOYSA-N 0.000 description 1
• 235000011957 flavonols Nutrition 0.000 description 1
• 238000000684 flow cytometry Methods 0.000 description 1
• 229960002011 fludrocortisone Drugs 0.000 description 1
• AAXVEMMRQDVLJB-BULBTXNYSA-N fludrocortisone Chemical compound O=C1CC[C@]2(C)[C@@]3(F)[C@@H](O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 AAXVEMMRQDVLJB-BULBTXNYSA-N 0.000 description 1
• 210000000497 foam cell Anatomy 0.000 description 1
• 238000009472 formulation Methods 0.000 description 1
• 238000001415 gene therapy Methods 0.000 description 1
• 230000002068 genetic effect Effects 0.000 description 1
• 239000008103 glucose Substances 0.000 description 1
• 235000013922 glutamic acid Nutrition 0.000 description 1
• 239000004220 glutamic acid Substances 0.000 description 1
• ZDXPYRJPNDTMRX-UHFFFAOYSA-N glutamine Natural products OC(=O)C(N)CCC(N)=O ZDXPYRJPNDTMRX-UHFFFAOYSA-N 0.000 description 1
• 235000004554 glutamine Nutrition 0.000 description 1
• 150000002334 glycols Chemical class 0.000 description 1
• 108091005608 glycosylated proteins Proteins 0.000 description 1
• 102000035122 glycosylated proteins Human genes 0.000 description 1
• 239000003102 growth factor Substances 0.000 description 1
• 150000008282 halocarbons Chemical class 0.000 description 1
• 230000004217 heart function Effects 0.000 description 1
• HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 description 1
• 229960000890 hydrocortisone Drugs 0.000 description 1
• 239000000017 hydrogel Substances 0.000 description 1
• 238000003384 imaging method Methods 0.000 description 1
• 230000005931 immune cell recruitment Effects 0.000 description 1
• 230000008088 immune pathway Effects 0.000 description 1
• 230000008629 immune suppression Effects 0.000 description 1
• 230000036039 immunity Effects 0.000 description 1
• 238000003018 immunoassay Methods 0.000 description 1
• 238000010166 immunofluorescence Methods 0.000 description 1
• 230000002055 immunohistochemical effect Effects 0.000 description 1
• 238000013388 immunohistochemistry analysis Methods 0.000 description 1
• 238000012309 immunohistochemistry technique Methods 0.000 description 1
• 238000012744 immunostaining Methods 0.000 description 1
• 230000001976 improved effect Effects 0.000 description 1
• 238000011534 incubation Methods 0.000 description 1
• 210000004969 inflammatory cell Anatomy 0.000 description 1
• 230000004054 inflammatory process Effects 0.000 description 1
• 230000000977 initiatory effect Effects 0.000 description 1
• 208000014674 injury Diseases 0.000 description 1
• 238000003780 insertion Methods 0.000 description 1
• 230000037431 insertion Effects 0.000 description 1
• 230000002452 interceptive effect Effects 0.000 description 1
• 239000013067 intermediate product Substances 0.000 description 1
• 208000021600 intervertebral disc degenerative disease Diseases 0.000 description 1
• 238000007918 intramuscular administration Methods 0.000 description 1
• 238000007912 intraperitoneal administration Methods 0.000 description 1
• 238000007913 intrathecal administration Methods 0.000 description 1
• 229940088976 invirase Drugs 0.000 description 1
• 229910052740 iodine Inorganic materials 0.000 description 1
• 239000011630 iodine Substances 0.000 description 1
• 239000003456 ion exchange resin Substances 0.000 description 1
• 229920003303 ion-exchange polymer Polymers 0.000 description 1
• 229910052742 iron Inorganic materials 0.000 description 1
• 238000002955 isolation Methods 0.000 description 1
• AGPKZVBTJJNPAG-UHFFFAOYSA-N isoleucine Natural products CCC(C)C(N)C(O)=O AGPKZVBTJJNPAG-UHFFFAOYSA-N 0.000 description 1
• 229960000310 isoleucine Drugs 0.000 description 1
• FABUFPQFXZVHFB-CFWQTKTJSA-N ixabepilone Chemical compound C/C([C@@H]1C[C@@H]2O[C@]2(C)CCC[C@@H]([C@@H]([C@H](C)C(=O)C(C)(C)[C@H](O)CC(=O)N1)O)C)=C\C1=CSC(C)=N1 FABUFPQFXZVHFB-CFWQTKTJSA-N 0.000 description 1
• 229960002014 ixabepilone Drugs 0.000 description 1
• MWDZOUNAPSSOEL-UHFFFAOYSA-N kaempferol Natural products OC1=C(C(=O)c2cc(O)cc(O)c2O1)c3ccc(O)cc3 MWDZOUNAPSSOEL-UHFFFAOYSA-N 0.000 description 1
• 210000002510 keratinocyte Anatomy 0.000 description 1
• 238000011862 kidney biopsy Methods 0.000 description 1
• 238000002372 labelling Methods 0.000 description 1
• 239000008101 lactose Substances 0.000 description 1
• 229960001627 lamivudine Drugs 0.000 description 1
• JTEGQNOMFQHVDC-NKWVEPMBSA-N lamivudine Chemical compound O=C1N=C(N)C=CN1[C@H]1O[C@@H](CO)SC1 JTEGQNOMFQHVDC-NKWVEPMBSA-N 0.000 description 1
• 239000002523 lectin Substances 0.000 description 1
• HPJKCIUCZWXJDR-UHFFFAOYSA-N letrozole Chemical compound C1=CC(C#N)=CC=C1C(N1N=CN=C1)C1=CC=C(C#N)C=C1 HPJKCIUCZWXJDR-UHFFFAOYSA-N 0.000 description 1
• 229960003881 letrozole Drugs 0.000 description 1
• 230000021633 leukocyte mediated immunity Effects 0.000 description 1
• 150000002632 lipids Chemical class 0.000 description 1
• 230000004130 lipolysis Effects 0.000 description 1
• 239000002502 liposome Substances 0.000 description 1
• 244000144972 livestock Species 0.000 description 1
• 238000011068 loading method Methods 0.000 description 1
• 238000011866 long-term treatment Methods 0.000 description 1
• 230000007774 longterm Effects 0.000 description 1
• 229960004525 lopinavir Drugs 0.000 description 1
• 239000000314 lubricant Substances 0.000 description 1
• 239000012139 lysis buffer Substances 0.000 description 1
• 235000019359 magnesium stearate Nutrition 0.000 description 1
• 239000000696 magnetic material Substances 0.000 description 1
• 238000012423 maintenance Methods 0.000 description 1
• 210000004962 mammalian cell Anatomy 0.000 description 1
• 239000002609 medium Substances 0.000 description 1
• 201000002699 melanoma in congenital melanocytic nevus Diseases 0.000 description 1
• 239000000155 melt Substances 0.000 description 1
• 238000002844 melting Methods 0.000 description 1
• 230000008018 melting Effects 0.000 description 1
• 230000003818 metabolic dysfunction Effects 0.000 description 1
• 230000002503 metabolic effect Effects 0.000 description 1
• 230000007102 metabolic function Effects 0.000 description 1
• 239000007769 metal material Substances 0.000 description 1
• 230000001394 metastastic effect Effects 0.000 description 1
• 208000021039 metastatic melanoma Diseases 0.000 description 1
• 206010061289 metastatic neoplasm Diseases 0.000 description 1
• 229930182817 methionine Natural products 0.000 description 1
• 244000005700 microbiome Species 0.000 description 1
• 230000002438 mitochondrial effect Effects 0.000 description 1
• 230000004898 mitochondrial function Effects 0.000 description 1
• 238000012986 modification Methods 0.000 description 1
• 230000004048 modification Effects 0.000 description 1
• 230000009456 molecular mechanism Effects 0.000 description 1
• 238000002887 multiple sequence alignment Methods 0.000 description 1
• 230000035772 mutation Effects 0.000 description 1
• UZWDCWONPYILKI-UHFFFAOYSA-N n-[5-[(4-ethylpiperazin-1-yl)methyl]pyridin-2-yl]-5-fluoro-4-(7-fluoro-2-methyl-3-propan-2-ylbenzimidazol-5-yl)pyrimidin-2-amine Chemical compound C1CN(CC)CCN1CC(C=N1)=CC=C1NC1=NC=C(F)C(C=2C=C3N(C(C)C)C(C)=NC3=C(F)C=2)=N1 UZWDCWONPYILKI-UHFFFAOYSA-N 0.000 description 1
• 210000000581 natural killer T-cell Anatomy 0.000 description 1
• 230000007896 negative regulation of T cell activation Effects 0.000 description 1
• 230000007935 neutral effect Effects 0.000 description 1
• 229960000689 nevirapine Drugs 0.000 description 1
• 229910052759 nickel Inorganic materials 0.000 description 1
• 229920001220 nitrocellulos Polymers 0.000 description 1
• 229960003301 nivolumab Drugs 0.000 description 1
• 230000004987 nonapoptotic effect Effects 0.000 description 1
• 231100000065 noncytotoxic Toxicity 0.000 description 1
• 230000002020 noncytotoxic effect Effects 0.000 description 1
• 238000003199 nucleic acid amplification method Methods 0.000 description 1
• VQWNELVFHZRFIB-UHFFFAOYSA-N odn 1826 Chemical compound O=C1NC(=O)C(C)=CN1C(O1)CC(O)C1COP(O)(=O)OC1CC(N2C(NC(=O)C(C)=C2)=O)OC1COP(O)(=O)OC1CC(N2C3=C(C(NC(N)=N3)=O)N=C2)OC1COP(O)(=O)OC1CC(N2C(N=C(N)C=C2)=O)OC1COP(O)(=O)OC1CC(N2C3=NC=NC(N)=C3N=C2)OC1COP(O)(=O)OC1CC(N2C3=C(C(NC(N)=N3)=O)N=C2)OC1COP(O)(=O)OC1CC(N2C(NC(=O)C(C)=C2)=O)OC1COP(O)(=O)OC1CC(N2C(N=C(N)C=C2)=O)OC1COP(O)(=O)OC1CC(N2C(N=C(N)C=C2)=O)OC1COP(O)(=O)OC1CC(N2C(NC(=O)C(C)=C2)=O)OC1COP(O)(=O)OC(C(O1)COP(O)(=O)OC2C(OC(C2)N2C3=C(C(NC(N)=N3)=O)N=C2)COP(O)(=O)OC2C(OC(C2)N2C(N=C(N)C=C2)=O)COP(O)(=O)OC2C(OC(C2)N2C3=NC=NC(N)=C3N=C2)COP(O)(=O)OC2C(OC(C2)N2C3=C(C(NC(N)=N3)=O)N=C2)COP(O)(=O)OC2C(OC(C2)N2C(NC(=O)C(C)=C2)=O)COP(O)(=O)OC2C(OC(C2)N2C3=NC=NC(N)=C3N=C2)COP(O)(=O)OC2C(OC(C2)N2C(N=C(N)C=C2)=O)COP(O)(=O)OC2C(OC(C2)N2C(N=C(N)C=C2)=O)COP(O)(=O)OC2C(OC(C2)N2C(NC(=O)C(C)=C2)=O)COP(O)(O)=O)CC1N1C=C(C)C(=O)NC1=O VQWNELVFHZRFIB-UHFFFAOYSA-N 0.000 description 1
• ZQPPMHVWECSIRJ-KTKRTIGZSA-N oleic acid Chemical class CCCCCCCC\C=C/CCCCCCCC(O)=O ZQPPMHVWECSIRJ-KTKRTIGZSA-N 0.000 description 1
• 210000004248 oligodendroglia Anatomy 0.000 description 1
• 231100000590 oncogenic Toxicity 0.000 description 1
• 230000002246 oncogenic effect Effects 0.000 description 1
• 239000003960 organic solvent Substances 0.000 description 1
• 229940061338 palbociclib 100 mg Drugs 0.000 description 1
• 230000003076 paracrine Effects 0.000 description 1
• 239000012188 paraffin wax Substances 0.000 description 1
• 230000005298 paramagnetic effect Effects 0.000 description 1
• 229960002621 pembrolizumab Drugs 0.000 description 1
• 239000000137 peptide hydrolase inhibitor Substances 0.000 description 1
• 210000005259 peripheral blood Anatomy 0.000 description 1
• 239000011886 peripheral blood Substances 0.000 description 1
• 210000004303 peritoneum Anatomy 0.000 description 1
• 230000002688 persistence Effects 0.000 description 1
• 230000002085 persistent effect Effects 0.000 description 1
• 238000002823 phage display Methods 0.000 description 1
• 239000000546 pharmaceutical excipient Substances 0.000 description 1
• 230000000144 pharmacologic effect Effects 0.000 description 1
• NTGBUUXKGAZMSE-UHFFFAOYSA-N phenyl n-[4-[4-(4-methoxyphenyl)piperazin-1-yl]phenyl]carbamate Chemical compound C1=CC(OC)=CC=C1N1CCN(C=2C=CC(NC(=O)OC=3C=CC=CC=3)=CC=2)CC1 NTGBUUXKGAZMSE-UHFFFAOYSA-N 0.000 description 1
• COLNVLDHVKWLRT-UHFFFAOYSA-N phenylalanine Natural products OC(=O)C(N)CC1=CC=CC=C1 COLNVLDHVKWLRT-UHFFFAOYSA-N 0.000 description 1
• 230000035479 physiological effects, processes and functions Effects 0.000 description 1
• 229950010773 pidilizumab Drugs 0.000 description 1
• 239000006187 pill Substances 0.000 description 1
• 229960005095 pioglitazone Drugs 0.000 description 1
• 239000013612 plasmid Substances 0.000 description 1
• 102000040430 polynucleotide Human genes 0.000 description 1
• 108091033319 polynucleotide Proteins 0.000 description 1
• 239000002157 polynucleotide Substances 0.000 description 1
• 239000000244 polyoxyethylene sorbitan monooleate Substances 0.000 description 1
• 235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 description 1
• 229920000053 polysorbate 80 Polymers 0.000 description 1
• 229940068968 polysorbate 80 Drugs 0.000 description 1
• 229920006316 polyvinylpyrrolidine Polymers 0.000 description 1
• 230000029279 positive regulation of transcription, DNA-dependent Effects 0.000 description 1
• 229960005205 prednisolone Drugs 0.000 description 1
• OIGNJSKKLXVSLS-VWUMJDOOSA-N prednisolone Chemical compound O=C1C=C[C@]2(C)[C@H]3[C@@H](O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 OIGNJSKKLXVSLS-VWUMJDOOSA-N 0.000 description 1
• 229960004618 prednisone Drugs 0.000 description 1
• XOFYZVNMUHMLCC-ZPOLXVRWSA-N prednisone Chemical compound O=C1C=C[C@]2(C)[C@H]3C(=O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 XOFYZVNMUHMLCC-ZPOLXVRWSA-N 0.000 description 1
• 230000000750 progressive effect Effects 0.000 description 1
• 230000002062 proliferating effect Effects 0.000 description 1
• 230000035755 proliferation Effects 0.000 description 1
• 230000002035 prolonged effect Effects 0.000 description 1
• 230000001737 promoting effect Effects 0.000 description 1
• 239000003380 propellant Substances 0.000 description 1
• 238000000746 purification Methods 0.000 description 1
• 235000005875 quercetin Nutrition 0.000 description 1
• 229960001285 quercetin Drugs 0.000 description 1
• 150000003254 radicals Chemical class 0.000 description 1
• 239000003247 radioactive fallout Substances 0.000 description 1
• 238000010814 radioimmunoprecipitation assay Methods 0.000 description 1
• 230000003439 radiotherapeutic effect Effects 0.000 description 1
• 239000011541 reaction mixture Substances 0.000 description 1
• 230000007420 reactivation Effects 0.000 description 1
• 230000009467 reduction Effects 0.000 description 1
• 230000022532 regulation of transcription, DNA-dependent Effects 0.000 description 1
• 230000008521 reorganization Effects 0.000 description 1
• 230000008439 repair process Effects 0.000 description 1
• 229950003687 ribociclib Drugs 0.000 description 1
• 238000002702 ribosome display Methods 0.000 description 1
• 229960000311 ritonavir Drugs 0.000 description 1
• NCDNCNXCDXHOMX-XGKFQTDJSA-N ritonavir Chemical compound N([C@@H](C(C)C)C(=O)N[C@H](C[C@H](O)[C@H](CC=1C=CC=CC=1)NC(=O)OCC=1SC=NC=1)CC=1C=CC=CC=1)C(=O)N(C)CC1=CSC(C(C)C)=N1 NCDNCNXCDXHOMX-XGKFQTDJSA-N 0.000 description 1
• 229960004586 rosiglitazone Drugs 0.000 description 1
• 239000012723 sample buffer Substances 0.000 description 1
• QWAXKHKRTORLEM-UGJKXSETSA-N saquinavir Chemical compound C([C@@H]([C@H](O)CN1C[C@H]2CCCC[C@H]2C[C@H]1C(=O)NC(C)(C)C)NC(=O)[C@H](CC(N)=O)NC(=O)C=1N=C2C=CC=CC2=CC=1)C1=CC=CC=C1 QWAXKHKRTORLEM-UGJKXSETSA-N 0.000 description 1
• 230000035945 sensitivity Effects 0.000 description 1
• 235000004400 serine Nutrition 0.000 description 1
• 230000006807 siRNA silencing Effects 0.000 description 1
• 230000019491 signal transduction Effects 0.000 description 1
• 208000017520 skin disease Diseases 0.000 description 1
• 239000004055 small Interfering RNA Substances 0.000 description 1
• 235000019812 sodium carboxymethyl cellulose Nutrition 0.000 description 1
• 229920001027 sodium carboxymethylcellulose Polymers 0.000 description 1
• 239000001509 sodium citrate Substances 0.000 description 1
• NLJMYIDDQXHKNR-UHFFFAOYSA-K sodium citrate Chemical compound O.O.[Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O NLJMYIDDQXHKNR-UHFFFAOYSA-K 0.000 description 1
• FHHPUSMSKHSNKW-SMOYURAASA-M sodium deoxycholate Chemical compound [Na+].C([C@H]1CC2)[C@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@@H](CCC([O-])=O)C)[C@@]2(C)[C@@H](O)C1 FHHPUSMSKHSNKW-SMOYURAASA-M 0.000 description 1
• 239000001540 sodium lactate Substances 0.000 description 1
• 229940005581 sodium lactate Drugs 0.000 description 1
• 235000011088 sodium lactate Nutrition 0.000 description 1
• 239000000600 sorbitol Substances 0.000 description 1
• 239000007921 spray Substances 0.000 description 1
• 239000003381 stabilizer Substances 0.000 description 1
• 238000011255 standard chemotherapy Methods 0.000 description 1
• 238000010561 standard procedure Methods 0.000 description 1
• 239000008107 starch Substances 0.000 description 1
• 235000019698 starch Nutrition 0.000 description 1
• 229960001203 stavudine Drugs 0.000 description 1
• 238000011476 stem cell transplantation Methods 0.000 description 1
• 239000008223 sterile water Substances 0.000 description 1
• 230000004936 stimulating effect Effects 0.000 description 1
• 238000010254 subcutaneous injection Methods 0.000 description 1
• 239000007929 subcutaneous injection Substances 0.000 description 1
• 235000000346 sugar Nutrition 0.000 description 1
• 150000005846 sugar alcohols Polymers 0.000 description 1
• 150000008163 sugars Chemical class 0.000 description 1
• 229910021653 sulphate ion Inorganic materials 0.000 description 1
• 230000036561 sun exposure Effects 0.000 description 1
• 230000001629 suppression Effects 0.000 description 1
• 230000004083 survival effect Effects 0.000 description 1
• 230000009885 systemic effect Effects 0.000 description 1
• 239000000454 talc Substances 0.000 description 1
• 229910052623 talc Inorganic materials 0.000 description 1
• 235000012222 talc Nutrition 0.000 description 1
• 210000002435 tendon Anatomy 0.000 description 1
• 229960004556 tenofovir Drugs 0.000 description 1
• VCMJCVGFSROFHV-WZGZYPNHSA-N tenofovir disoproxil fumarate Chemical compound OC(=O)\C=C\C(O)=O.N1=CN=C2N(C[C@@H](C)OCP(=O)(OCOC(=O)OC(C)C)OCOC(=O)OC(C)C)C=NC2=C1N VCMJCVGFSROFHV-WZGZYPNHSA-N 0.000 description 1
• 238000012360 testing method Methods 0.000 description 1
• 150000001467 thiazolidinediones Chemical class 0.000 description 1
• 239000002562 thickening agent Substances 0.000 description 1
• 229960001196 thiotepa Drugs 0.000 description 1
• 235000008521 threonine Nutrition 0.000 description 1
• 229960000838 tipranavir Drugs 0.000 description 1
• SUJUHGSWHZTSEU-FYBSXPHGSA-N tipranavir Chemical compound C([C@@]1(CCC)OC(=O)C([C@H](CC)C=2C=C(NS(=O)(=O)C=3N=CC(=CC=3)C(F)(F)F)C=CC=2)=C(O)C1)CC1=CC=CC=C1 SUJUHGSWHZTSEU-FYBSXPHGSA-N 0.000 description 1
• 230000000699 topical effect Effects 0.000 description 1
• 230000001988 toxicity Effects 0.000 description 1
• 231100000419 toxicity Toxicity 0.000 description 1
• 231100000765 toxin Toxicity 0.000 description 1
• 239000003053 toxin Substances 0.000 description 1
• 108700012359 toxins Proteins 0.000 description 1
• 230000009261 transgenic effect Effects 0.000 description 1
• 229960005294 triamcinolone Drugs 0.000 description 1
• GFNANZIMVAIWHM-OBYCQNJPSA-N triamcinolone Chemical compound O=C1C=C[C@]2(C)[C@@]3(F)[C@@H](O)C[C@](C)([C@@]([C@H](O)C4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 GFNANZIMVAIWHM-OBYCQNJPSA-N 0.000 description 1
• QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 1
• 230000001960 triggered effect Effects 0.000 description 1
• LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 1
• 229960001641 troglitazone Drugs 0.000 description 1
• GXPHKUHSUJUWKP-UHFFFAOYSA-N troglitazone Chemical compound C1CC=2C(C)=C(O)C(C)=C(C)C=2OC1(C)COC(C=C1)=CC=C1CC1SC(=O)NC1=O GXPHKUHSUJUWKP-UHFFFAOYSA-N 0.000 description 1
• GXPHKUHSUJUWKP-NTKDMRAZSA-N troglitazone Natural products C([C@@]1(OC=2C(C)=C(C(=C(C)C=2CC1)O)C)C)OC(C=C1)=CC=C1C[C@H]1SC(=O)NC1=O GXPHKUHSUJUWKP-NTKDMRAZSA-N 0.000 description 1
• 230000005751 tumor progression Effects 0.000 description 1
• OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 description 1
• 229940121358 tyrosine kinase inhibitor Drugs 0.000 description 1
• 239000005483 tyrosine kinase inhibitor Substances 0.000 description 1
• 150000004917 tyrosine kinase inhibitor derivatives Chemical class 0.000 description 1
• 210000000626 ureter Anatomy 0.000 description 1
• 239000004474 valine Substances 0.000 description 1
• 230000004218 vascular function Effects 0.000 description 1
• 230000001457 vasomotor Effects 0.000 description 1
• 230000002618 waking effect Effects 0.000 description 1
• 239000001993 wax Substances 0.000 description 1
• 239000002023 wood Substances 0.000 description 1
• 229960000523 zalcitabine Drugs 0.000 description 1
• HBOMLICNUCNMMY-XLPZGREQSA-N zidovudine Chemical compound O=C1NC(=O)C(C)=CN1[C@@H]1O[C@H](CO)[C@@H](N=[N+]=[N-])C1 HBOMLICNUCNMMY-XLPZGREQSA-N 0.000 description 1